QuantRx(R) Biomedical to Participate in MEDICA, International Medical Trade Fair, in Düsseldorf, Germany
DOYLESTOWN, PA -- (MARKET WIRE) -- November 07, 2006 -- QuantRx® Biomedical Corporation (OTCBB: QTXB), an emerging leader in the research and development of medical diagnostic platforms and products, today announced that the company will participate in MEDICA 2006, the world's leading medical trade fair, to be held November 15-18, 2006, at the Düsseldorf Trade Fair Centre in Germany.
QuantRx Biomedical can be found in Hall 16, Stand D26-11, with the Oregon Bioscience Association and will be meeting with potential distribution partners for its Point of Care Rapid Lateral Flow and PADKit product lines as well as prospective partners for its patented oral-fluid collection device, specifically designed for point-of-care testing.
"By participating in MEDICA, QuantRx Biomedical is focused on seeking European and Asian partners to expand the channels of distribution for our product lines and technology platforms, as well as broaden awareness of our company in global markets," Walter Witoshkin, QuantRx president and chief executive officer, said, adding that the company's plans call for an early 2007 start to a series of product introductions based on its existing innovative technology platforms.
About QuantRx Biomedical
QuantRx Biomedical Corporation (OTCBB: QTXB) is an emerging leader in the research and development of medical diagnostics, specializing in creating, acquiring and commercializing diagnostic platforms and developing products, based on its core intellectual property, for both professional and consumer use. The company's technology portfolio includes rapid point-of-care testing products that bring medical information directly to the healthcare provider or the patient; genome-based diagnostics chips for medical professionals and institutions; PAD technology for diagnosis and treatment of women's health concerns and other medical needs; and diagnostic imaging products for the positron emission tomography (PET) market.
QuantRx has corporate offices in Doylestown, Pennsylvania, and its research and development center in Portland, Oregon. Additionally, the Company holds significant positions in FluoroPharma, Inc., a Boston-based molecular imaging company, and Genomics USA, Inc., a Chicago-based developer of microarray technology for DNA testing.
This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. QuantRx does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.